APPENDIX 2.

May 10, 2005

To Whom It May Concern:

Statement of Commitment

The Invitrogen Corporation Grand Island, New York site employs methods and controls used for the manufacturing, processing, packaging and holding of cell culture media, sera, and reagents that are in substantial compliance with requirements of the Quality System Regulations (cGMP) as described in 21 CFR, Part 820 of the Food and Drug Regulations. The site is registered with the United States Food and Drug Administration as a manufacturer of medical devices. In addition, Invitrogen's Quality System has been assessed and found to conform to ISO 9001:2000 requirements. Therefore, Invitrogen's Grand Island, New York site has been granted a Certificate of Registration by the British Standards Institute.

Sincerely,

Keith D. Gittermann

Keith D. Gittermann
Director, Regulatory Affairs

gmpltr04/compliance

Invitrogen Corporation
3175 Staley Road • Grand Island, NY 14072 • p: 716.774.6700 • f: 716.774.6682 • www.invitrogen.com